Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KF-0210 |
Synonyms | |
Therapy Description |
KF-0210 is an antagonist of the prostaglandin E2 receptor 4 (EP4), which potentially enhances anti-tumor immune response and tumor growth inhibition (Cancer Res (2023) 83 (7_Supplement): 2330). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KF-0210 | KF0210|KF 0210 | KF-0210 is an antagonist of the prostaglandin E2 receptor 4 (EP4), which potentially enhances anti-tumor immune response and tumor growth inhibition (Cancer Res (2023) 83 (7_Supplement): 2330). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04713891 | Phase I | KF-0210 Atezolizumab + KF-0210 | A Study of KF-0210 in Advanced Solid Tumors Patients | Completed | AUS | 0 |